Cargando…

The clinical profile of benralizumab in the management of severe eosinophilic asthma

Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menzella, Francesco, Lusuardi, Mirco, Galeone, Carla, Facciolongo, Nicola, Zucchi, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933597/ https://www.ncbi.nlm.nih.gov/pubmed/27612492 http://dx.doi.org/10.1177/1753465816667659

Ejemplares similares

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Tailored therapy for severe asthma
por: Menzella, Francesco, et al.
Publicado: (2015)

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
por: Menzella, Francesco, et al.
Publicado: (2015)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Bronchial thermoplasty and the role of airway smooth muscle: are we on the right direction?
por: Menzella, Francesco, et al.
Publicado: (2017)

Real world effectiveness of benralizumab on respiratory function and asthma control
por: Menzella, Francesco, et al.
Publicado: (2021)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
por: Menzella, Francesco, et al.
Publicado: (2019)

Heat-induced necrosis after bronchial thermoplasty: a new concern?
por: Menzella, Francesco, et al.
Publicado: (2018)

Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report
por: Menzella, Francesco, et al.
Publicado: (2018)

Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report
por: Facciolongo, Nicola, et al.
Publicado: (2015)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?
por: Menzella, Francesco, et al.
Publicado: (2017)

Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Towards precision medicine: The application of omics technologies in asthma management
por: Scelfo, Chiara, et al.
Publicado: (2018)

Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for “Omics” Technology?
por: Galeone, Carla, et al.
Publicado: (2018)

Eosinophilic infiltrate in a patient with severe Legionella pneumonia as a levofloxacin-related complication: a case report
por: Facciolongo, Nicola, et al.
Publicado: (2010)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
por: Noorduyn, Stephen G., et al.
Publicado: (2021)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
por: Gómez-Bastero Fernández, Ana, et al.
Publicado: (2022)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling
por: Facciolongo, Nicola, et al.
Publicado: (2022)

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
por: Menzella, Francesco, et al.
Publicado: (2019)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)

The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review
por: Menzella, Francesco, et al.
Publicado: (2021)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
por: Chan, Rory, et al.
Publicado: (2023)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
por: Caruso, Cristiano, et al.
Publicado: (2022)

Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
por: Liu, Wanshu, et al.
Publicado: (2019)

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma
por: Yamada, Hideyasu, et al.
Publicado: (2021)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
por: Vultaggio, Alessandra, et al.
Publicado: (2023)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma
por: Goyack, Laura, et al.
Publicado: (2023)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iq6cr3b68ln9h169l8e3cr5e72